CCL Stock Price: Carnival slumps as major coronavirus vaccine study fails
Premium|Take advantage of 50% OFF on your first month.
Start your subscription and get access to all our original articles.
You have reached your limit of 5 free articles for this month.
Get Premium without limits for only $9.99 for the first month
Access all our articles, insights, and analysts.
UNLOCK OFFER- NYSE:CCL drops 3.44% as cruise-line industry takes a hit despite broader markets rebounding.
- AstraZeneca coronavirus vaccine reveals adverse reaction to patients as it halts testing.
NYSE:CCL continues its tumultuous year as the fate of the stock remains tied to the possibility of a coronavirus vaccine. The cruise industry remains landlocked though and threatens to be out of commission until a vaccine is created. Shares of Carnival are now up 126% off its 52-week lows of $7.80 – but still down 65% off its 52-week highs of $51.94 which shows how beaten down companies in this sector are. Carnival is now trading above its 60-day and 200-day moving averages showing that it is on an upward trajectory – but much of that could have been on the optimism of an impending vaccine.
The cruise industry can be lumped in with the airlines and hotels as some of the hardest hit by the novel coronavirus around the world. Currently, optimistic travellers can book cruises for next year although this is contingent on agencies like the CDC which has recently extended its no-sail order through to September 30th. In some countries that are either beyond the worst of COVID-19 or were never affected, to begin with, cruises have been able to resume service. Specifically, the European arm of Carnival Cruise Lines in Italy and Germany have either re-engaged in cruise service or are scheduled to in the next couple of months.
CCL stock news
For CCL, as long as the coronavirus is present in the United States, a large number of its business will remain closed as the CDC continues to extend the no-sail orders. Industry rivals Norwegian Cruise Lines (NASDAQ:NCLH) and Royal Caribbean (NYSE:RCL) continue to struggle this year and just like Carnival, are well off their pre-COVID trading levels. The failure of AstraZeneca’s (NYSE:AZN) coronavirus vaccine should not be seen as a total game stopper for cruises but the further we are from a successful vaccine, the longer this industry will suffer to be profitable.
- NYSE:CCL drops 3.44% as cruise-line industry takes a hit despite broader markets rebounding.
- AstraZeneca coronavirus vaccine reveals adverse reaction to patients as it halts testing.
NYSE:CCL continues its tumultuous year as the fate of the stock remains tied to the possibility of a coronavirus vaccine. The cruise industry remains landlocked though and threatens to be out of commission until a vaccine is created. Shares of Carnival are now up 126% off its 52-week lows of $7.80 – but still down 65% off its 52-week highs of $51.94 which shows how beaten down companies in this sector are. Carnival is now trading above its 60-day and 200-day moving averages showing that it is on an upward trajectory – but much of that could have been on the optimism of an impending vaccine.
The cruise industry can be lumped in with the airlines and hotels as some of the hardest hit by the novel coronavirus around the world. Currently, optimistic travellers can book cruises for next year although this is contingent on agencies like the CDC which has recently extended its no-sail order through to September 30th. In some countries that are either beyond the worst of COVID-19 or were never affected, to begin with, cruises have been able to resume service. Specifically, the European arm of Carnival Cruise Lines in Italy and Germany have either re-engaged in cruise service or are scheduled to in the next couple of months.
CCL stock news
For CCL, as long as the coronavirus is present in the United States, a large number of its business will remain closed as the CDC continues to extend the no-sail orders. Industry rivals Norwegian Cruise Lines (NASDAQ:NCLH) and Royal Caribbean (NYSE:RCL) continue to struggle this year and just like Carnival, are well off their pre-COVID trading levels. The failure of AstraZeneca’s (NYSE:AZN) coronavirus vaccine should not be seen as a total game stopper for cruises but the further we are from a successful vaccine, the longer this industry will suffer to be profitable.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.